Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Completed · Phase 2

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or refractory lymphoproliferative disorders.

Key facts

Study ID

NCT00052572

Run by

Memorial Sloan Kettering Cancer Center

People needed

35

Starts

2002-10-01

Expected to finish

2007-07-01

Last updated by the study team

2013-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Vermont Cancer Center at University of Vermont — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.